Bupivacaine HCI without epinephrine
Drug100 mg administered via injection into the surgical site.
NCT Number: NCT04911062
This is a Phase 2, multicenter study in subjects undergoing an open lumbar decompression surgery.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 2
Arizona Research Center, Phoenix, Arizona, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
100 mg administered via injection into the surgical site.
HTX-011 (bupivacaine/meloxicam) dose up to 200 mg/6 mg administered via application into the surgical site.
Applicator for instillation.
Time frame: From the time the subject signs the ICF through the Day 29 Visit
Time frame: Baseline through 120 hours
Time frame: Baseline through 120 hours
Time frame: Baseline through 120 hours
Time frame: Baseline through 120 hours
Time frame: Baseline through 120 hours
Heron Therapeutics
Industry
A Phase 2, Two-Part, Multicenter Study of HTX-011 in Spinal Surgery
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01307215
Neurologic Manifestations, Pain
Hamilton, Ontario, Canada
View Trial DetailsNCT05831449
Bunion, Foot Deformities
Salt Lake City, Utah, United States
View Trial DetailsNCT06028126
Anesthesia, Local, Chemically-Induced Disorders
Calgary, Alberta, Canada
View Trial DetailsNCT07418671
Erector Spinae Plane Block, Neurologic Manifestations
Cairo, Cairo Governorate, Egypt
View Trial Details